title: Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections.
abstract: Trimethoprim-sulfamethoxazole (TMP-SMZ) is recommended as the treatment of choice for Stenotrophomonas maltophilia infections. However, when the administration of TMP-SMZ is not possible, alternative treatment options for S. maltophilia infections has not been clearly established. We compare the efficacy of tigecycline treatment with TMP-SMZ in nosocomial S. maltophilia infections during a 3-year period. For the treatment of S. maltophilia infection, 26 (57.8%) patients received TMP-SMZ and 19 (42.2%) patients received tigecycline. Culture positivity rate was 95.7% in TMP-SMZ group and 70.6% in tigecycline group at the seventh day (P = 0.028), whereas 26.3% versus 18.8% at the fourteenth day (P = 0.700). Clinical improvement was observed 69.2% in TMP-SMZ group and 68.4% in tigecycline group at the fourteenth day (P = 0.954). Mortality rates at the thirtieth day were respectively, 30.8 and 21.1% in TMP-SMZ and tigecycline groups (P = 0.517). There were no significant differences in mortality and clinical response rates between TMP-SMZ and tigecycline treatment. Tigecycline can be considered as an alternative option beyond TMP-SMZ in treatment of S. maltophilia infections.
authors: Department of Infectious Diseases and Clinical Microbiology, Türkiye Yüksek İhtisas Education and Research Hospital, Ankara, Turkey.
authors: Yasemin Tezer
authors: YT
authors: Tekçe
authors: Ayşe
authors: A
authors: Erbay
authors: Hatice
authors: H
authors: Cabadak
authors: Süha
authors: S
authors: Sen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D020615:Stenotrophomonas maltophilia / Q000187:drug effects* / Q000302:isolation & purification; D015996:Survival Rate; D000078304:Tigecycline; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
chemical_list: D000890:Anti-Infective Agents; D000078304:Tigecycline; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D008911:Minocycline